Strategic agreement is expected to reduce costs, preserve expertise, and streamline operations. | WHO | WHAT | WHERE | WHEN | WHY | | --- | --- | --- | --- | --- | | Nuwellis, Inc. (Nasdaq: NUWE) and KDI | Outsourcing manufacturing and | Manufacturing | May 9, | To strengthen operational efficiency, | | Precision | assembly of key Aquadex product | operations will transition to KDI's facility. | 2025 | preserve product expertise, and reduce | | Manufacturing | components. | | | costs. | MINNEAPOLIS, May 12, ...

Core Insights - UFP Technologies, Inc. reported a strong financial performance for Q1 2025, with net income of $17.2 million, or $2.21 per diluted share, compared to $12.7 million, or $1.64 per diluted share in Q1 2024, reflecting a 35.4% increase in net income [1][3][8] - Net sales for the first quarter reached $148.1 million, a 41.1% increase from $105.0 million in the same period last year, driven primarily by a 50.4% growth in sales to the medical market [1][3][5] Financial Performance - The company's operating income increased by 45.2% to $23.1 million in Q1 2025, up from $15.9 million in Q1 2024 [3][5] - Adjusted net income rose by 40.1% to $19.2 million in Q1 2025, compared to $13.7 million in Q1 2024 [3][21] - Gross profit margin slightly decreased to 28.5% in Q1 2025 from 28.6% in Q1 2024 [3] Market Segments - The MedTech business segment experienced a significant growth of 50%, with strong demand in the Safe Patient Handling area [2][3] - Other market segments, including Interventional and Surgical, Infection Prevention, Orthopedics, and Advanced Wound Care, also reported growth exceeding 25% [2] - Organic sales growth for the overall company was 2.3%, with a specific organic growth of 5.4% in the MedTech segment despite a 6% decline in Robotic Surgery sales [2][3] Strategic Developments - The company secured an exclusive manufacturing agreement with its second-largest customer for a significant portion of its Safe Patient Handling business through June 2030 [2] - UFP Technologies has expanded its manufacturing operations in the Dominican Republic to meet growing demand, including plans for a fifth building at its La Romana Robotic Surgery campus [2] - The company is actively pursuing acquisition opportunities, having recently completed a small acquisition that complements its previous purchase of AJR Enterprises [2][3] Non-GAAP Financial Measures - Adjusted EBITDA for Q1 2025 increased by 45.9% to $30.2 million from $20.7 million in Q1 2024 [8][22] - Adjusted SG&A expenses rose by 27.5% to $16.3 million, but as a percentage of sales, it decreased to 11.0% from 12.2% in the same period last year [3][19]

NEWBURYPORT, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ: UFPT), an innovative designer and custom manufacturer of components for medical devices, sterile packaging, and other highly engineered products, today announced the Company plans to report financial results for the first quarter ended March 31, 2025 on May 6, 2025 prior to market open. The Company will hold a conference call to discuss results the same day at 10:00 AM Eastern time. Conference Call Information:Date: Tuesd ...

Core Viewpoint - Senseonics Holdings, Inc. is set to release its first quarter 2025 financial results on May 8, 2025, after market close, indicating ongoing developments in its financial performance and product offerings [1]. Group 1: Financial Results Announcement - The company will announce its first quarter 2025 financial results after market close on May 8, 2025 [1]. - A conference call to discuss the financial performance will take place at 4:30 p.m. (Eastern Time) on the same day, which will also be available via webcast [2]. Group 2: Company Overview - Senseonics is a medical technology company focused on developing and manufacturing long-term implantable continuous glucose monitoring (CGM) systems for diabetes management [3]. - The company's CGM systems, Eversense 365 and Eversense E3, feature a small sensor that is implanted under the skin and communicates with a smart transmitter, sending glucose data to a mobile app every 5 minutes [3].

Core Points - Integer Holdings Corporation plans to release its financial and operational results for the first quarter of 2025 on April 24, 2025, at 7 a.m. CT / 8 a.m. ET [1] - Following the results release, a webcast will be hosted by Integer management at 8 a.m. CT / 9 a.m. ET to discuss the results and other forward-looking information [1] - Integer is one of the largest medical device contract development and manufacturing organizations (CDMO) globally, focusing on cardiac rhythm management, neuromodulation, and cardio and vascular markets [4] Conference Call Details - An audio replay of the conference call will be available for seven days, accessible by dialing (800) 770-2030 or (609) 800-9909 with Conference ID 3120125 [2] - The conference call will also be available live or via archived replay on the Investor Relations section of the Integer website [2][3] - Domestic and international dial-in numbers for the conference call are provided, along with the Conference ID [5] Company Overview - Integer Holdings Corporation is committed to enhancing patient lives by providing innovative, high-quality products and solutions [4] - The company serves as a strategic partner to medical device companies and OEMs, with notable brands including Greatbatch Medical® and Lake Region Medical® [4]